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Modern multicomponent reactions for better drug
syntheses
Tryfon Zarganes-Tzitzikas and Alexander Dömling*
Multicomponent reaction (MCR) technology is now widely recognized for its impact on drug discovery
projects and is strongly endorsed by industry as well as academia. However, still relatively few products
based on MCRs are marketed or under development. This provides tremendous opportunities for organic
chemists to shorten synthetic pathways, thus reducing the cost-of-goods considerably. A recent example
of the HCV drug Telaprevir is highlighted where introduction of two MCRs could lead to a shortening of
the synthesis route by more than 50%.
The ever growing structural complexity of modern drugs has
led to an increase in the diﬃculty of synthetic eﬀorts for their
production (Fig. 1). This general trend can be rationalized as
more complex proteins and enzymes are emerging as viable
drug targets and there is an increasing need for higher selecti-
vity and potency of compounds.
The large scale GMP synthesis of complex drugs is almost
automatically reflected in the considerably higher cost-of-
goods. Sometimes, however, a cleverly designed synthetic
pathway can lead to rapid, convergent, and cheaper syntheses
of otherwise diﬃcult and lengthy-to-access drug targets. An
interesting recent case is the 2013 FDA approved hepatitis C
NS3 protease inhibitor Telaprevir.
Hepatitis C is a viral infectious disease aﬀecting more than
200 million people worldwide and is currently treated by a
combination of PEGylated interferon and ribavirin. However, a
significant number of patients do not respond to this therapy
due to adverse eﬀects or viral rebound caused by resistant
strains. The recent approval of two peptidic HCV NS3 protease
inhibitors Telaprevir and Boceprevir has shifted the HCV treat-
ment paradigm and gives patients new and powerful treatment
options. The reported technical synthesis of Telaprevir involves
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a lengthy, highly linear strategy relying on standard peptide
chemistry and entails more than 20 linear steps.1 For example,
the central bicyclic proline derivative is synthesized in racemic
form via a nine-step sequence. The desired enantiomer is only
obtained after chiral HPLC separation. Optimization of the
synthesis of Telaprevir could significantly lower the production
costs, thereby making this highly needed drug available to an
increased proportion of the world population in the future.
Here we highlight the work of two independent groups
towards significant improvements in the synthesis of the HCV
drug Telaprevir 1. It has to be noted that both syntheses are
currently being investigated for large scale preparation by a
pharmaceutical company. Recently Orru and Ruijter et al. from
the VU University Amsterdam disclosed a highly eﬃcient and
stereoselective synthesis of Telaprevir (Incivek®) employing
the combined use of biocatalysts and multicomponent reac-
tions (MCRs). The synthesis comprises of only eleven steps in
total compared to twenty-four in the originally reported
procedure.2–4 The significance of the work is a reduction by
more than half the steps while comprising a “greener” process
which can be additionally translated into a considerably lower
cost-of-goods.
A retrosynthetic analysis of 1 involving two MCRs is pres-
ented in Fig. 2. The required starting materials for the key
Ugi-type 3CR were the carboxylic acid 2, cyclic imine 3, and
isocyanide 4. The acid 2 could be accessed by standard peptide
chemistry, while the chiral imine 3 was generated in situ from
commercially available 5 by the enzyme MAO-N catalyzed oxi-
dation. The isocyanide 4 was accessed via a Passerini three-
component reaction (P-3CR) of compounds 6 and 7, and acetic
acid.
Coupling of pyrazinecarboxylic acid 9 and L-cyclohexylgly-
cine methyl ester 10 followed by saponification aﬀorded 11 in
excellent yield. Subsequent coupling with L-tert-leucine methyl
ester 12 and saponification furnished the required optically
pure acid 2. The Orru and Ruijter group was able to signifi-
cantly increase both the atom and step economy and the
overall yield (74% vs. 11% over four steps) of the acid 2 com-
pared to the already known synthesis1 (Fig. 3).
The construction of the isocyanide fragment 4 was done in
three steps in which a Passerini 3-component reaction (P-3CR)
played a key role. Commercial (S)-2-amino-1-pentanol 8 was
transformed to formamide 13 by N-formylation. Following the
work of Ngouansavanh and Zhu,5 the in situ oxidation of
alcohol 13 and a P-3CR was performed in one pot giving
access to 14. Both the alcohol oxidation and the Passerini reac-
Fig. 2 MCR retrosynthetic analysis of Telaprevir (Incivek®).
Fig. 3 Synthesis of acid 2. Reagents and conditions: (a) BOP, Et3N, DMF,
98%; (b) NaOH, THF–H2O–MeOH, 95%; (c) H-Tle-OMe 12, EDC, HOAt,
DMF, 84%; (d) NaOH, THF–H2O–MeOH, 95%. BOP = benzotriazole-1-
yl-oxy-tris-(dimethylamino)-phosphonium hexaﬂuorophosphate, DMF =
dimethylformamide, EDC = 1-ethyl-3-(3 dimethyl-aminopropyl)carbo-
diimide, HOAt = 1-hydroxy-7-azabenzotriazole.
Fig. 1 Structural complexity of marketed or late-stage HCV NS3
inhibitors.
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tion were performed in CH2Cl2. Thus, one-pot Dess–Martin
oxidation/Passerini reaction of 13 furnished 14 in 60% yield.
Dehydration then aﬀorded the required isocyanide 4 in very
good yield (87%). Importantly, no racemization of the C3
stereocenter in 4 was observed. The diastereomeric stereocen-
ter of 4 in C4 will be removed at a later stage of the synthesis.
The crucial building block 4 was thus accessible in only three
steps from commercially available starting materials (Fig. 4).
The last step towards the three-component Ugi-type coup-
ling envisaged in the retrosynthesis is described below. The
commercial amine 5 was oxidized to imine 3 (94% ee) by
MAO-N as previously described.6–8 Reacting cyclic Schiﬀ base 3
with the acid 2 and the isocyanide 4 gave the advanced inter-
mediate 15. Finally, cleavage of the acetate followed by Dess–
Martin oxidation gave Telaprevir 1 as a 83 : 13 : 4 mixture of
diastereomers, with one minor diastereomer derived from the
incomplete stereoinduction of the Ugi-type 3CR, and the other
from the minor enantiomer of imine 3. Chromatography
allowed straightforward separation of the diastereomers to
aﬀord pure Telaprevir 1 in 80% yield over the last two steps
(Fig. 5). The above synthesis comprises of only eleven steps in
total (technical 24), with seven steps in the longest linear
sequence and a yield of 45% starting from 10. In conclusion,
the MCR approach that the group of Orru and Ruijter proposes
gives access to Telaprevir 1 in higher yields and with higher
eﬃciency than any previously disclosed process. Furthermore,
the chiral information used for the preparation is derived from
readily available and inexpensive building blocks, making the
process a highly eﬀective approach to such prolyl dipeptides.
Recently Banfi et al. disclosed an alternative pathway to Tel-
aprevir combining biocatalysis and MCRs.9,10 Their strategy
involved the construction of the backbone of the C-terminus of
the target compounds while subsequently forming the bicyclic
pyrrolidine. Biocatalytic desymmetrization of meso diol 16 fol-
lowed by a short sequence of standard transformations gives
alcohol 17.11
Next, in situ oxidation of 17 to the aldehyde is done in a
Passerini-reaction to aﬀord 18 as a mixture of the diastereo-
isomer ratio of a/b = 2 : 1. After the azide reduction of 18a, an
intramolecular O to N migration occurs to give the amidoalco-
hol 19. Cyclization via the mesylate 20 proceeded in excellent
yields to give 21 (Fig. 6). After deprotection and oxidation,
aldehyde 22 is formed. A Passerini reaction takes place in the
next step involving compound 22, cyclopropyl isocyanide 24,
and acetic acid 25 producing compound 23, which after three
steps is converted into Telaprevir. As an additional benefit of
the synthesis the volatile cyclopropylisocyanide is not isolated
but produced in situ from the formamide precursor. The
second route by Banfi et al. although longer than the first one
is highlighting alternative synthetic processes which might
find use due to intellectual property management and/or
better yields and stereoselectivities.
The reduction of the steps of the technical total synthesis
of Telaprevir by more than 1/2 using two convergent MCRs in
combination with biocatalysis is indeed an intriguing piece of
applied chemistry. It should be noted that Telaprevir is an out-
standingly complex example of process improvement by MCR;
however, an increasing number of drugs have been recently
synthesized by this technology.12–17
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Fig. 4 Synthesis of isocyanide 4. Reagents and conditions: (a) EtOCHO,
Δ, 99%; (b) DMP, cyclopropyl isocyanide, CH2Cl2, 60%; (c) triphosgene,
NMM, CH2Cl2, −30 °C, 87%. DMP = Dess–Martin periodinane, NMM =
N-methylmorpholine.
Fig. 5 Synthesis of 1. Reagents and conditions: (a) monoamine oxidase
(MAO-N), 100 mM KPO4 buﬀer, pH = 8.0, 37 °C; (b) 2, 4, CH2Cl2, 76%;
(c) K2CO3, MeOH; (d) DMP, CH2Cl2, 80% over two steps. DMP = Dess–
Martin periodinane.
Fig. 6 Synthesis of 1 by Banﬁ et al. Reagents and conditions: (a) (i)
DMSO, oxalyl chloride in DCM, (ii) (S)-2-isocyanopentyl benzoate, boric
acid in CH3CN, 92% diastereoisomeric mixture a/b = 2 : 1; (b) (i) PPh3–
H2O, (ii) NMM, L-Boc-t-leucine, PyBoP, 78%; (c) methanesulfonyl chlor-
ide, Et3N in DCM; (d) (i) NaH, DMF, 78%; (e) 7, 24 and 22 in DCM, r.t.
DMF = dimethylformamide, NMM = N-methylmorpholine, PyBoP = ben-
zotriazol-1-yl-oxytripyrrolidinophosphonium hexaﬂuorophosphate.
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